Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Soybean phytosterol is a botanical extract derived from soybeans, primarily consisting of a mixture of plant sterols such as beta-sitosterol, campesterol, and stigmasterol. It is being developed as a pharmaceutical product, notably under the brand name Pureixiao, for the treatment of chronic nonbacterial prostatitis (NIH category III). The therapeutic effect is attributed to its anti-inflammatory properties and its ability to inhibit 5-alpha-reductase, thereby reducing the production of dihydrotestosterone (DHT) and alleviating symptoms of prostatic congestion and inflammation. Clinical evaluation in China has focused on its efficacy in improving voiding symptoms and reducing pelvic pain in men with chronic prostatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on soybean phytosterol.